HOUSE 2623117th CongressReferred to the Subcommittee on Health.

Cameron’s Law

Last Action: 4/19/2021

Actions

2021-04-19Referred to the Subcommittee on Health.
2021-04-16Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2021-04-16Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2021-04-16Introduced in House
2021-04-16Introduced in House

CRS Summary

As of 2021-04-16 (00)

Cameron's Law

This bill increases the rate of the tax credit for clinical testing expenses for rare diseases or conditions from 25% to 50% (orphan drug tax credit).

The bill also requires the Centers for Disease Control and Prevention to complete a study to evaluate the feasibility of enhancing and expanding the infrastructure to track the epidemiology of rare diseases or conditions.

Cosponsors (2)

FRED UPTON (R-MI)
Don Bacon (R-NE)

Subjects

Business expenses
Congressional oversight
Drug safety, medical device, and laboratory regulation
Drug therapy
Government studies and investigations
Income tax credits
Medical research
Medical tests and diagnostic methods
Research and development

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.